HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint

This article was originally published in The Rose Sheet

Executive Summary

P&G’s planned purchase of Merck KGaA’s consumer health care business will grow its personal health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories. CEO David Taylor framed the acquisition as another step in the firm's ongoing portfolio shakeup.

You may also be interested in...

With Its Own Home, Pfizer Consumer Health Gets Higher Profile For Sale

By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."

Turnaround Lagging, Vitamin Shoppe Heeds Hedge Fund Direction

Shah Capital Management, with 17.7% of Vitamin Shopper shares, and Vintage Capital Management , which owns 14.8%, will appoint three of five replacements to Vitamin Shoppe's board and will have a say in the other two. Vitamin Shoppe also will sell its under-performing contract manufacturing unit and tender, subject to ratification by Shah and Vintage, up to $25m of its common stock at a per-share price not to exceed $5.

P&G’s Q3: Negative Pricing, ‘Change In Tone’ Have Analysts Spooked

Firm’s slowing organic growth and negative pricing impacts in the third quarter reflect much-talked-about pressures in health and beauty care. However, the scope of the challenges is becoming clearer, and analysts are questioning whether P&G’s “not business as usual” response will be enough.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts